PMID: 8581415Sep 1, 1995Paper

Tissue-specific effects of anti-CD4 therapy in induction of allograft unresponsiveness in high and low responder rats

Transplant Immunology
D Yin, C G Fathman

Abstract

In these experiments, we studied the role of anti-CD4 (Ox38) monoclonal antibody in the prevention of heart and/or kidney allograft rejection in low (ACI) and high (Lewis) responder rats. In low responder ACI rats, donor-specific tolerance for heart and kidney allografts (individually or in combination) was achieved by pretransplant anti-CD4 therapy. In high responder Lewis rats, anti-CD4 therapy alone (or combined with anti-CD8 (Ox8), thymectomy or total lymphoid irradiation) did not prevent first-set rejection of heart allografts. This difference was correlated with a more profound and longer lasting CD4+ cell depletion in the low responder strain. Anti-CD4 treatment, however, produced tolerance of kidney transplants in high responder rats. Additionally, anti-CD4 treatment induced tolerance to heart (as well as kidney) allografts in Lewis recipients of combined kidney and heart allografts from ACI. The effects of anti-CD4 treatment thus depend upon the recipient responder status as well as the organs transplanted and the order of transplantation.

References

Jun 1, 1991·Transplantation·B M Hall
Feb 1, 1991·The Journal of Experimental Medicine·S E AltersC G Fathman
Feb 1, 1989·Immunological Reviews·B J Roser
Jun 1, 1993·Immunological Reviews·M J DallmanH M Charlton
Nov 1, 1993·Transplantation·R W GruessnerD E Sutherland

❮ Previous
Next ❯

Citations

Nov 1, 1996·The Journal of Experimental Medicine·N R KriegerC G Fathman
Oct 18, 2000·The Journal of Clinical Investigation·B A PietraR G Gill
Aug 12, 1998·The Journal of Surgical Research·N R KriegerC G Fathman
Oct 4, 2018·Tissue Engineering. Part a·Rei KuwabaraHiroo Iwata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.